Program
cariprazine
Also written as “Cariprazine”, “MP-214 3mg” and “MP-214 6mg”.
Its studies are mostly in Schizophrenia · Depressive Disorder, Major · Bipolar Disorder · Mania · Depression, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 291 open or running | phase 3since Jan 27, 2010 | Nov 27, 2006 | Mar 2027phase 3 · NCT04777357 |
| Tanabe Pharma | 60 open or running | phase 3since Jun 19, 2012 | Mar 15, 2009 | none ahead |
| Gedeon Richter Plc. | 21 open or running | phase 3since Jan 24, 2019 | Jun 13, 2014 | Dec 15, 2026phase 3 · NCT03817502 |
| Bostal Drug Delivery | 11 open or running | phase 3since Jul 15, 2026 | Jul 15, 2026 | Aug 2027phase 3 · NCT07722728 |
| Humanis Saglık Anonim Sirketi | 10 open or running | phase 1since Jul 1, 2026 | Jul 1, 2026 | none ahead |
| Mapi Pharma | 11 open or running | phase 2since Aug 28, 2025 | Aug 28, 2025 | Dec 31, 2026phase 2 · NCT07185815 |
| Whanin Pharmaceutical | 10 open or running | phase 3since Nov 26, 2021 | Nov 26, 2021 | none ahead |
Also a collaborator on its studies: gedeon-richter-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 25 studies since Nov 27, 2006.
- Jan 28, 20162 phase 3 studies in Bipolar DisorderAbbVie · NCT02670551, NCT02670538
- Jun 5, 2018Phase 3 study in ManiaAbbVie · NCT03573297 · 901 enrolled · United States, Bulgaria, Korea, Republic of and more
- Jul 10, 2018Phase 3 study in SchizophreniaAbbVie · NCT03593213 · 587 enrolled · United States, Bulgaria, Korea, Republic of and more
- Nov 8, 20182 phase 3 studies in Depressive Disorder, MajorAbbVie · NCT03738215, NCT03739203
- Jan 24, 2019Phase 3 study in SchizophreniaGedeon Richter Plc. · NCT03817502 · 330 planned · United States, Bulgaria, Colombia and more
- Mar 19, 2020Phase 1 study in Autism Spectrum DisorderAbbVie · NCT04382885 · 24 enrolled · United States
- Feb 26, 2021Phase 3 study in DepressionAbbVie · NCT04777357 · 380 planned · United States, Puerto Rico, Russia
- Jul 7, 2021Phase 2 study in Generalized Anxiety DisorderAbbVie · NCT04965272 · United States
- Nov 26, 2021Whanin Pharmaceutical's first study: phase 3 study in SchizophreniaNew to Whanin PharmaceuticalWhanin Pharmaceutical · NCT05168007 · 342 enrolled · Korea, Republic of
- May 6, 2022Phase 3 study in SchizophreniaAbbVie · NCT05368558 · 34 enrolled · Japan, Taiwan
- Jun 28, 2022Phase 3 study in Autism Spectrum DisorderAbbVie · NCT05439616 · 161 enrolled · United States, Puerto Rico
- Aug 28, 2025Mapi Pharma's first study: phase 2 study in SchizophreniaNew to Mapi PharmaMapi Pharma · NCT07185815 · 24 planned · India, Israel
- Jul 1, 2026Humanis Saglık Anonim Sirketi's first study: phase 1 study in SCHIZOPHRENIA 1 (Disorder)New to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT07691190 · 32 enrolled · India
- Jul 15, 2026Bostal Drug Delivery's first study: phase 3 study in SchizophreniaNew to Bostal Drug DeliveryBostal Drug Delivery · NCT07722728 · 84 planned
Ahead
- Dec 15, 2026Primary completion: phase 3 study in SchizophreniaGedeon Richter Plc. · NCT03817502
- Dec 31, 2026Primary completion: phase 2 study in SchizophreniaMapi Pharma · NCT07185815
- Mar 2027Primary completion: phase 3 study in DepressionAbbVie · NCT04777357
- Aug 2027Primary completion: phase 3 study in SchizophreniaBostal Drug Delivery · NCT07722728
TargetBeta
“Dopamine D3 receptor modulator; Dopamine D2 receptor modulator”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
| rotigotinerule | UCB | phase 4 | 64 |
| Pramipexolerule | Boehringer Ingelheim | phase 4 | 44 |
| ABBV-932 | AbbVie | phase 2 | 10 |
Studies
All 41 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07722728Schizophrenia | 3 | Not yet recruiting | Bostal Drug Delivery | Aug 2027 | 84 |
| NCT07691190SCHIZOPHRENIA 1 (Disorder) · India | 1 | Completed | Humanis Saglık Anonim Sirketi | Jun 2, 2026 | 32 |
| NCT07185815Schizophrenia · India, Israel | 2 | Recruiting | Mapi Pharma | Dec 31, 2026 | 24 |
| NCT05439616Autism Spectrum Disorder · United States, Puerto Rico | 3 | Completed | AbbVie | Oct 4, 2024 | 161 |
| NCT05368558Schizophrenia · Japan, Taiwan | 3 | Terminated | AbbVie | Sep 20, 2024 | 34 |
| NCT05168007Schizophrenia · Korea, Republic of | 3 | UNKNOWN | Whanin Pharmaceutical | Jul 17, 2023 | 342 |
| NCT04965272Generalized Anxiety Disorder · United States | 2 | Withdrawn | AbbVie | Aug 24, 2021 | 0 |
| NCT04777357Depression · United States, Puerto Rico, Russia | 3 | Recruiting | AbbVie | Mar 2027 | 380 |
| NCT04382885Autism Spectrum Disorder · United States | 1 | Completed | AbbVie | Dec 10, 2021 | 24 |
| NCT03817502Schizophrenia · United States, Bulgaria, Colombia and more | 3 | Recruiting | Gedeon Richter Plc. | Dec 15, 2026 | 330 |
| NCT03739203Depressive Disorder, Major · United States, Canada, Czechia and more | 3 | Completed | AbbVie | Sep 6, 2021 | 752 |
| NCT03738215Depressive Disorder, Major · United States, Bulgaria, Estonia and more | 3 | Completed | AbbVie | Sep 30, 2021 | 759 |
| NCT03593213Schizophrenia · United States, Bulgaria, Korea, Republic of and more | 3 | Terminated | AbbVie | Feb 11, 2021 | 587 |
| NCT03573297Mania · United States, Bulgaria, Korea, Republic of and more | 3 | Completed | AbbVie | Sep 5, 2022 | 901 |
| NCT02670551Bipolar Disorder · United States, Bulgaria, Estonia and more | 3 | Completed | AbbVie | Jul 19, 2017 | 488 |
| NCT02670538Bipolar Disorder · United States, Bulgaria, Croatia and more | 3 | Completed | AbbVie | Jan 18, 2018 | 493 |
| NCT02165098Pharmacokinetic Profile · United Kingdom | 1 | Completed | Gedeon Richter Plc. | Feb 2016 | 160 |
| NCT01838876Depressive Disorder, Major · United States, Puerto Rico | 3 | Completed | AbbVie | Jul 27, 2015 | 442 |
| NCT01715805Depressive Disorder, Major · United States, Puerto Rico | 3 | Completed | AbbVie | Jun 24, 2016 | 1,022 |
| NCT01626885Schizophrenia · Japan | 3 | Completed | Tanabe Pharma | Jun 2014 | 42 |
| NCT01626872Schizophrenia · Japan, South Korea, Taiwan | 3 | Completed | Tanabe Pharma | Oct 2016 | 254 |
| NCT01626859Schizophrenia · Japan | 3 | Completed | Tanabe Pharma | Aug 2013 | 38 |
| NCT01625897Schizophrenia · Japan | 3 | Completed | Tanabe Pharma | Mar 2015 | 125 |
| NCT01625000Schizophrenia · Japan, South Korea, Taiwan | 3 | Completed | Tanabe Pharma | Aug 2015 | 512 |
| NCT01469377Depressive Disorder, Major · United States, Estonia, Finland and more | 2 | Completed | AbbVie | Dec 12, 2013 | 819 |
| NCT01412060Schizophrenia · United States, India, Romania and more | 3 | Completed | AbbVie | Sep 3, 2014 | 765 |
| NCT01396447Bipolar Disorder · United States, Bulgaria, Canada and more | 2 | Completed | AbbVie | Jan 10, 2014 | 584 |
| NCT01376076Schizophrenia · United States | 1 | Completed | AbbVie | Feb 2012 | 129 |
| NCT01104779Schizophrenia · United States, Colombia, India and more | 3 | Completed | AbbVie | Dec 15, 2011 | 446 |
| NCT01104792Schizophrenia · United States, Colombia, India and more | 3 | Completed | AbbVie | Jan 31, 2013 | 752 |
| NCT01104766Schizophrenia · United States, Romania, Russian Federation and more | 3 | Completed | AbbVie | Dec 20, 2011 | 617 |
| NCT01059539Mania · United States, Hungary, Poland and more | 3 | Completed | AbbVie | Feb 29, 2012 | 403 |
| NCT01058668Mania · United States, Croatia, Romania and more | 3 | Completed | AbbVie | Dec 2011 | 497 |
| NCT01058096Bipolar Disorder · United States, India | 3 | Completed | AbbVie | Jul 2011 | 323 |
| NCT00862992Schizophrenia · Japan | 2 | Completed | Tanabe Pharma | Sep 2009 | 34 |
| NCT00854100Depressive Disorder, Major · United States | 2 | Completed | AbbVie | Dec 6, 2010 | 231 |
| NCT00852202Bipolar Disorder · United States | 2 | Completed | AbbVie | Jun 15, 2010 | 234 |
| NCT00839852Schizophrenia · United States, India, Malaysia and more | 2 | Completed | AbbVie | Aug 31, 2010 | 97 |
| NCT00694707Schizophrenia · United States, India, Malaysia and more | 2 | Completed | AbbVie | Aug 31, 2009 | 732 |
| NCT00488618Bipolar Disorder · United States | 2 | Completed | AbbVie | Jul 2008 | 238 |
| NCT00404573Schizophrenia · United States | 2 | Completed | AbbVie | Aug 2007 | 375 |
How it is read
Names in the registry
- “Cariprazine”, 25 entries
- “MP-214 3mg”, 3 entries
- “MP-214 6mg”, 3 entries
- “MP-214 9mg”, 3 entries
- “MP-214”, 2 entries
Conditions, from the studies’ own filings
- Schizophrenia, 21 studies
- Depressive Disorder, Major, 6 studies
- Bipolar Disorder, 6 studies
- Mania, 3 studies
- Depression, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.